Spots Global Cancer Trial Database for Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

Official Title: Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

Study ID: NCT01653964

Conditions

Breast Cancer

Interventions

Molecular breast imaging

Study Description

Brief Summary: The primary objective of this work is to determine if half-dose Molecular Breast Imaging (MBI) performed with 4 mCi Tc-99m sestamibi with or without Wide Beam Reconstruction applied can achieve image quality and diagnostic accuracy non-inferior to that of standard MBI performed with 8 millicurie (mCi) Tc-99m sestamibi.

Detailed Description: Recent implementation of dose reduction strategies for Molecular Breast Imaging now allow performance of MBI at an administered dose of 8 mCi Tc-99m sestamibi, which is reduced from the previously used doses of 20-30 mCi. In order to safely introduce MBI as a screening modality, we aim to perform MBI using 4 mCi Tc-99m sestamibi. An image processing algorithm called Wide Beam Reconstruction (WBR) has been tailored for MBI technology with the goal of allowing either the current administered dose or current acquisition time to be reduced by half.